T1	Participants 43 92	male patients with diffuse large B-cell lymphoma.
T2	Participants 127 138	multicentre
T3	Participants 364 471	321 patients [161 randomized to the treatment group (TG), 160 to the observation group (OG)], 295 data sets
T4	Participants 659 675	(DLBCL) subgroup
T5	Participants 789 827	in male patients of the DLBCL subgroup
T6	Participants 1417 1442	survival in male patients
